(Q40649930)

English

Effects of tobramycin solution for inhalation on global ratings of quality of life in patients with cystic fibrosis and Pseudomonas aeruginosa infection

scientific article published on April 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

22 September 2017

Effects of tobramycin solution for inhalation on global ratings of quality of life in patients with cystic fibrosis and Pseudomonas aeruginosa infection (English)

1 reference

Europe PubMed Central

22 September 2017

cystic fibrosis

0 references

Pseudomonas aeruginosa

1 reference

based on heuristic

inferred from title

Alexandra L Quittner

1

object named as

Alexandra L Quittner

1 reference

Europe PubMed Central

22 September 2017

author name string

Anne Buu

2

1 reference

Europe PubMed Central

22 September 2017

publication date

1 April 2002

1 reference

Europe PubMed Central

22 September 2017

Pediatric Pulmonology

1 reference

Europe PubMed Central

22 September 2017

33

1 reference

Europe PubMed Central

22 September 2017

269-276

1 reference

Europe PubMed Central

22 September 2017

4

1 reference

Europe PubMed Central

22 September 2017

International comparison of median age at death from cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.10074

21 January 2018

Treatment of cystic fibrosis in the adult

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.10074

21 January 2018

Cystic fibrosis: current survival and population estimates to the year 2000.

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.10074

21 January 2018

Self-rated health and mortality: a review of twenty-seven community studies

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.10074

21 January 2018

Quality of life in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.10074

21 January 2018

Quality of life as a treatment outcome in patients with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.10074

21 January 2018

Development of a disease specific health related quality of life measure for adults and adolescents with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.10074

21 January 2018

Translation and linguistic validation of a disease-specific quality of life measure for cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.10074

21 January 2018

The changing epidemiology of cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.10074

21 January 2018

Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.10074

21 January 2018

The quality of well-being in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.10074

21 January 2018

Quality of well-being before and after antibiotic treatment of pulmonary exacerbation in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.10074

21 January 2018

Identifiers

10.1002/PPUL.10074

1 reference

Europe PubMed Central

22 September 2017

1 reference

Europe PubMed Central

22 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40649930&oldid=1904130109"